These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37962644)

  • 1. Engineered phage enzymes against drug-resistant pathogens: a review on advances and applications.
    Hassannia M; Naderifar M; Salamy S; Akbarizadeh MR; Mohebi S; Moghadam MT
    Bioprocess Biosyst Eng; 2024 Mar; 47(3):301-312. PubMed ID: 37962644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriophage endolysins as a novel class of antibacterial agents.
    Borysowski J; Weber-Dabrowska B; Górski A
    Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phage-Encoded Endolysins.
    Abdelrahman F; Easwaran M; Daramola OI; Ragab S; Lynch S; Oduselu TJ; Khan FM; Ayobami A; Adnan F; Torrents E; Sanmukh S; El-Shibiny A
    Antibiotics (Basel); 2021 Jan; 10(2):. PubMed ID: 33525684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections.
    Gondil VS; Harjai K; Chhibber S
    Int J Antimicrob Agents; 2020 Feb; 55(2):105844. PubMed ID: 31715257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gram-negative endolysins: overcoming the outer membrane obstacle.
    Sisson HM; Jackson SA; Fagerlund RD; Warring SL; Fineran PC
    Curr Opin Microbiol; 2024 Apr; 78():102433. PubMed ID: 38350268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Screening, and Characterization of Engineered Phage Endolysins with Extracellular Antibacterial Activity against Gram-Negative Bacteria.
    Sui B; Wang X; Zhao T; Zhen J; Ren H; Liu W; Zhang X; Zhang C
    Appl Environ Microbiol; 2023 Jul; 89(7):e0058123. PubMed ID: 37338346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications.
    Donovan DM
    Recent Pat Biotechnol; 2007; 1(2):113-22. PubMed ID: 19075835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.
    Oliveira H; São-José C; Azeredo J
    Viruses; 2018 May; 10(6):. PubMed ID: 29844287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriophages, phage endolysins and antimicrobial peptides - the possibilities for their common use to combat infections and in the design of new drugs.
    Mirski T; Lidia M; Nakonieczna A; Gryko R
    Ann Agric Environ Med; 2019 Jun; 26(2):203-209. PubMed ID: 31232046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria.
    Gerstmans H; Rodríguez-Rubio L; Lavigne R; Briers Y
    Biochem Soc Trans; 2016 Feb; 44(1):123-8. PubMed ID: 26862197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteriophages as a potential substitute for antibiotics: A comprehensive review.
    Kushwaha SO; Sahu SK; Yadav VK; Rathod MC; Patel D; Sahoo DK; Patel A
    Cell Biochem Funct; 2024 Apr; 42(3):e4022. PubMed ID: 38655589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.
    Liu H; Hu Z; Li M; Yang Y; Lu S; Rao X
    J Biomed Sci; 2023 Apr; 30(1):29. PubMed ID: 37101261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteriophage Endolysin: A Powerful Weapon to Control Bacterial Biofilms.
    Liu B; Guo Q; Li Z; Guo X; Liu X
    Protein J; 2023 Oct; 42(5):463-476. PubMed ID: 37490161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Advantages and Challenges of Using Endolysins in a Clinical Setting.
    Murray E; Draper LA; Ross RP; Hill C
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33920965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens.
    Briers Y; Walmagh M; Van Puyenbroeck V; Cornelissen A; Cenens W; Aertsen A; Oliveira H; Azeredo J; Verween G; Pirnay JP; Miller S; Volckaert G; Lavigne R
    mBio; 2014 Jul; 5(4):e01379-14. PubMed ID: 24987094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of modular bacteriophage endolysins from Myoviridae phages OBP, 201φ2-1 and PVP-SE1.
    Walmagh M; Briers Y; dos Santos SB; Azeredo J; Lavigne R
    PLoS One; 2012; 7(5):e36991. PubMed ID: 22615864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence-Function Relationships in Phage-Encoded Bacterial Cell Wall Lytic Enzymes and Their Implications for Phage-Derived Product Design.
    Vázquez R; García E; García P
    J Virol; 2021 Jun; 95(14):e0032121. PubMed ID: 33883227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taking aim on bacterial pathogens: from phage therapy to enzybiotics.
    Hermoso JA; García JL; García P
    Curr Opin Microbiol; 2007 Oct; 10(5):461-72. PubMed ID: 17904412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endolysins as antimicrobials.
    Nelson DC; Schmelcher M; Rodriguez-Rubio L; Klumpp J; Pritchard DG; Dong S; Donovan DM
    Adv Virus Res; 2012; 83():299-365. PubMed ID: 22748813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage endolysins are adapted to specific hosts and are evolutionarily dynamic.
    Oechslin F; Zhu X; Dion MB; Shi R; Moineau S
    PLoS Biol; 2022 Aug; 20(8):e3001740. PubMed ID: 35913996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.